

PROPOSED AGENDA*

THURSDAY, JANUARY 3, 2019

18:00 – 21:00 Welcome Reception

FRIDAY, JANUARY 4, 2019

6:45 – 7:30 Breakfast

7:30 – 8:00 The Year 2018 in Review

SESSION 1: LATEST CLINICAL TRIAL RESULTS

8:00 – 8:30 MGL 3196

8:30 – 9:00 Aramchol

9:00 – 9:30 NGM 282

9:30 – 10:00 GS 9674 FXR

10:00 – 10:20 Break – Exhibit Hall/Poster Viewing

SESSION 2: THE LIVER AND ITS METABOLIC CONDITIONING

10:20 – 10:40 AcetylCoA carboxylase activity and metabolic, inflammatory and hepatic consequences: Prospects for NASH Therapy

10:40 – 11:00 Current status on pharmacological options to weight loss agents

11:00 – 11:45 Free Paper Session – 3 Oral Presentations

11:45 – 16:00 Free Time

SESSION 3: EXPERIMENTAL SESSION

16:00 – 16:30 Selective PPAR modulators – Hype or Hope?

16:30 – 17:00 Extracellular Vesicles as mediators of inflammation

**Detailed agenda and presenting faculty to be finalized in fall of 2018*

PROPOSED AGENDA*

- | | |
|---------------|--|
| 17:00 – 17:30 | Signals from preclinical models and success of NASH trials |
| 17:30 – 18:00 | 3D Tissue modeling and precision cut liver slices: Will they help drug testing for NASH? |
| 18:00 – 18:20 | Break – Exhibit Hall |

FINDING THE NASH PATIENTS: CASE FOR & AGAINST SCREENING FOR NASH

- | | |
|---------------|---|
| 18:20 – 18:30 | The case against screening for NASH |
| 18:30 – 18:40 | The case in favor of screening for NASH |

NASH DRUGS REIMBURSEMENT: PRESENTATIONS & PANEL DISCUSSION

- | | |
|---------------|---|
| 18:40 – 19:05 | Barriers to overcome for reimbursement of NASH drugs |
| 19:05 – 19:30 | Lessons learned from CV and diabetes trials |
| 19:30 – 19:55 | European perspective on reimbursement policies: Market specifics of Germany, UK, and France |

SATURDAY, JANUARY 5, 2019

- | | |
|-------------|-----------|
| 6:45 – 7:30 | Breakfast |
|-------------|-----------|

SESSION 1: REFINING CLINICAL TRIAL DESIGN

- | | |
|---------------|---|
| 7:30 – 8:00 | Maximizing efficacy and minimizing placebo response |
| 8:00 – 8:30 | Challenges in conducting trials in East Asia, India, and Japan |
| 8:30 – 9:00 | Current and future trends in hepatic MRI using a background of cardiac MRI development |
| 9:00 – 9:30 | Assessing DILI in NASH trials |
| 9:30 – 10:00 | Genetic testing: Any use for sub phenotyping or risk stratification in clinical trials? |
| 10:00 – 10:20 | Break – Exhibit Hall/Poster Viewing |

*Detailed agenda and presenting faculty to be finalized in fall of 2018

PROPOSED AGENDA*

10:20 – 10:40	Understanding the methods of and need for CV risk assessment
10:40 – 11:00	Second Harmonic Generation fully quantitative histopathology assessment for NASH
11:00 – 11:45	Free Paper Session – 3 Oral Presentations
11:45 – 16:00	Free Time

SESSION 2: NEW PHARMACOLOGICAL TARGETS

DUAL AGONIST AND INJECTABLES

16:00 – 16:20	GLP-1 – Semaglutide
16:20 – 16:40	GLP-1R Glucan receptor agonists MEDI 0382
16:40 – 17:00	Novel FGF21 Constructs

SESSION 3: THE CONTINUOUS SEARCH FOR ANTIFIBROTIC AGENTS

17:00 – 17:20	Integrin antagonism as an Antifibrotic Therapy
17:20 – 17:40	GPR40 and 84G Cell coupled receptor modulators, PBI-4050
17:40 – 18:00	SGM-1019 S
18:00 – 18:20	Break – Exhibit Hall
18:20 – 19:35	Free Paper Session – 3 Oral Presentations
19:35	Closing Remarks
	Adjourn

**Detailed agenda and presenting faculty to be finalized in fall of 2018*